HBM Healthcare Investments Reports Robust Quarterly Growth

HBM Healthcare Investments announces a strong quarterly performance with an expected profit of CHF 238 million. The Net Asset Value (NAV) per share saw a 13% increase to CHF 306.20, while the share price rose by 8.9% to CHF 236.00, marking a discount of around 23% to NAV. Total net assets surpassed CHF 2 billion as of 30 June 2026.

Performance was mainly driven by the listed portfolio companies, contributing CHF 183 million, fueled by momentum in the biotechnology sector and renewed investor interest in healthcare. Private portfolio companies added CHF 105 million to earnings, notably through Eli Lilly's acquisition of Curevo Vaccine, resulting in a value gain of CHF 32 million.

Additionally, a private company financing round contributed a CHF 70 million valuation increase, despite CHF 22 million in valuation adjustments. The portfolio's strength is shown by successful IPOs of Parabilis Medicines and Odyssey Therapeutics.